In part 2 of the study, the anti-tumor activity of TSR-022 in combination with TSR-042 is being evaluated in colorectal cancer, post-PD-1 melanoma, and post-PD-1 NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.